Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Cancer: Breakthrough Pain × Morphine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pain 6 Neoplasms 3 Cancer Pain 2 Waldenstrom Macroglobulinemia 1 Thrombocythemia, Essential 1 Substance Withdrawal Syndrome 1 Sezary Syndrome 1 Primary Myelofibrosis 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precancerous Conditions 1 Polycythemia Vera 1 Pdgfra-Associated Chronic Eosinophilic Leukemia 1 Pancreatic Neoplasms 1 Pain, Postoperative 1 Neoplasms, Plasma Cell 1 Neoplasm Metastasis 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Mycosis Fungoides 1 Multiple Myeloma 1 Monoclonal Gammopathy of Undetermined Significance 1 Lymphoproliferative Disorders 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Large B-Cell, Diffuse 1

Interventions

Morphine 1 Ketamine 1 Chitosan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02591017 2018-11-13

ONKEMI

University Hospital, Basel, Switzerland

Phase 3 Terminated

Cancer: Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon ⚡